BioLife Solutions, Inc. (BLFS)

NASDAQ: BLFS · IEX Real-Time Price · USD
21.96
-0.01 (-0.05%)
May 17, 2024, 4:00 PM EDT - Market closed
-0.05%
Market Cap 1.01B
Revenue (ttm) 137.30M
Net Income (ttm) -62.93M
Shares Out 46.03M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE 250.00
Dividend n/a
Ex-Dividend Date n/a
Volume 174,310
Open 22.02
Previous Close 21.97
Day's Range 21.63 - 22.11
52-Week Range 8.92 - 24.50
Beta 1.69
Analysts Strong Buy
Price Target 24.83 (+13.07%)
Earnings Date May 9, 2024

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproductio... [Read more]

Sector Healthcare
IPO Date Nov 22, 1989
Employees 409
Stock Exchange NASDAQ
Ticker Symbol BLFS
Full Company Profile

Financial Performance

In 2023, BLFS's revenue was $143.27 million, a decrease of -11.43% compared to the previous year's $161.76 million. Losses were -$66.43 million, -52.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price forecast is $24.83, which is an increase of 13.07% from the latest price.

Price Target
$24.83
(13.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioLife Solutions Reports First Quarter 2024 Financial Results

Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38%  and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40%  to 53%  and adjusted EBITDA...

8 days ago - PRNewsWire

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and...

17 days ago - PRNewsWire

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

BOTHELL, Wash. , April 18, 2024 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the ce...

4 weeks ago - PRNewsWire

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and...

2 months ago - PRNewsWire

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and posi...

2 months ago - PRNewsWire

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and...

3 months ago - PRNewsWire

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a ...

4 months ago - PRNewsWire

BioLife Solutions Reports Third Quarter 2023 Financial Results

Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

6 months ago - PRNewsWire

BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023

BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and ...

7 months ago - PRNewsWire

BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 millio...

7 months ago - PRNewsWire

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ALLKKZRTCRT
9 months ago - Benzinga

BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

10 months ago - PRNewsWire

BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023

BOTHELL, Wash. , July 27, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and...

10 months ago - PRNewsWire

BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities

BOTHELL, Wash. , June 14, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") a...

1 year ago - PRNewsWire

BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash. , June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc.  (NA...

1 year ago - PRNewsWire

BioLife Solutions Reports First Quarter 2023 Financial Results

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Dec...

1 year ago - PRNewsWire

BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023

BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and br...

1 year ago - PRNewsWire

BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results

Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and servi...

1 year ago - PRNewsWire

BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank

BOTHELL, Wash. , March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an...

1 year ago - PRNewsWire

BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023

BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and...

1 year ago - PRNewsWire

BioLife Solutions Launches Ultraguard™ -70°C Phase Change Material (PCM) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage

Exclusive global supplier of non-toxic, non-flammable PCM; first to operate at -70 ° C, meeting critical temperature requirement of biologic materials. BOTHELL, Wash.

1 year ago - PRNewsWire

BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences

BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

1 year ago - PRNewsWire

BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance

Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue grow...

1 year ago - PRNewsWire

BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL,...

1 year ago - PRNewsWire

BioLife Solutions Expands Intellectual Property Estate

7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash. , Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: B...

1 year ago - PRNewsWire